EUCTR2007-000416-91-FR进行中（未招募）1 期
A Phase I/II, Ascending, Multi-Dose Study of BMS-663513, An Agonistic Anti-CD137Monoclonal Antibody, Administered Every Three Weeks to Patients with Metastatic orLocally Advanced Solid Malignancies.Revised Protocol Number 07, incorporating Amendments 01, 02, 03, 04, 05, 06, 07 and Administrative Letter Dated 10-Mar-2006.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed written informed consent
- •- Target population
- •a) Able to comply with visits/procedures required by the protocol
- •b) Life expectancy of at least 3 months
- •c) ECOG performance status score 0 - 1 (Protocol Appendix 4).
- •d) Patients with histologic or cytologic diagnosis of an advanced solid malignancy
- •who have failed, refused or are unable to receive standard treatment.
- •NOTE: Patients enrolled after Amendment 7 is IRB approved are limited to:
- •Melanoma (must be anti-CTLA-4 naive),
- •Renal (clear cell) carcinoma, or
- •Epithelial carcinoma arising from the ovary, fallopian tube or peritoneum.
- •e) At least 1 site of measurable disease (excluding epithelial carcinoma who must
- •have at least 1 site of evaluable” disease)
- •f) A tumor paraffin embedded tissue block or 5 - 15 unstained slides from the tumor
- •tissue block (from the primary or a metastatic tumor) must be provided for
- •biomarker and predictive marker analyses. Note: If the tumor tissue block or unstained slides are not available or insufficient, additional fresh tumor tissue
- •could be collected during the optional pretreatment biopsy to satisfy this criteria
- •g) At least 4 weeks must have elapsed since the last chemotherapy, immunotherapy,
- •hormonal therapy, radiotherapy or major surgery, & the 1st day of BMS-663513 therapy. At least 6 weeks for nitrosoureas, mitomycin C & liposomal doxorubicin
- •h) Toxicities related to prior therapy must either have returned to = Grade 1, baseline or deemed irreversible
- •-Age and Sex
- •a) Men and women, who are at least 18 years of age.
- •- Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche & who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea >= 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level > 35 IU/mL. Even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an
- •intrauterine device or barrier methods (diaphragm, condoms, spermicides) to
- •prevent pregnancy or practicing abstinence or where partner is sterile (eg,
- •vasectomy), should be considered to be of child bearing potential.
- •- WOCBP must have a negative pregnancy test [minimum sensitivity 25 IU/L
- •or equivalent units of beta-human chorionic gonadatrophin (ßHCG)] within
- •72-hours prior to the start of study medication.
- •- Physical and laboratory test findings:
- •a) Adequate bone marrow function defined as:
- •Absolute neutrophil count (ANC) >= 1,500 cells/mm³
- •Platelet count >= 100,000 cells/mm³
- •Hemoglobin >= 9.0 g/dl
- •b) Adequate hepatic function defined as:
- •Total bilirubin =< 1.5 times the institutional upper limit of normal (IULN)
- •ALT, AST and alkaline phosphatase =< 2.5 times the IULN
- •c) Adequate renal function defined as:
- •Serum creatinine =< 1.5 times the IULN or
- •Calculated creatinine clearance of >= 60 mL/min/1.73m²
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Sex and Reproductive Status
- •a) WOCBP who are unwilling or unable to use an acceptable method to avoid
- •pregnancy for the entire study period and for up to 12 weeks after the study.
- •b) WOCBP using a prohibited contraceptive method.
- •c) Women who are pregnant or breastfeeding.
- •d) Women with a positive pregnancy test on enrollment or prior to study drug
- •administration.
- •e) Sexually active fertile men, whose partners are WOCBP, who are unwilling or
- •unable to use an acceptable method of birth control from the time of enrollment
- •and for 12 weeks after participation in the study.
- •- Medical History and Concurrent Diseases
- •a) Active infection or uncontrolled significant acute or chronic medical illness other
- •than current cancer that would prohibit safe administration of BMS-663513.
- •b) Any concurrent malignancy other than adequately treated basal or squamous cell
- •skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix.
- •Patients with a previous malignancy but without evidence of disease for >= 5 years
- •will be allowed to enter the trial.
- •c) History of autoimmune diseases including rheumatoid arthritis, lupus
- •erythermatosus, uveitis and autoimmune inflammatory eye disease, psoriasis,
- •multiple sclerosis, inflammatory bowel diseases, etc. Type I diabetes mellitus is
- •d) Known or suspected human immunodeficiency virus (HIV) positive.
- •e) Any current condition requiring the continued use of systemic or topical steroids
- •or the use of immunosuppressive agents (eg, cyclosporine and its analog, or
- •chemotherapy agents). All corticosteroid use must have been discontinued
- •>= 4 weeks prior to Day 1 of treatment.
- •f) Active/symptomatic brain metastasis. Patients with signs or symptoms suggestive
- •of brain metastasis are not eligible unless brain metastases are ruled out by
- •computerized axial tomography (CT) scan or magnetic resonance imaging (MRI).
- •Patients with stable brain metastasis and those who were previously treated with
- •radiotherapy or surgery must have no current evidence of active/symptomatic
- •brain metastasis and are off steroid therapy for at least 4 weeks prior to Day 1 of
- •g) Uncontrolled or significant cardiovascular disease including myocardial infarction
- •within 6 months, uncontrolled angina, Class III-IV New York Heart Association
- •(NYHA) congestive heart failure (Appendix 5) and clinically significant
- •ventricular arrhythmias.
- •h) Any other sound medical, psychiatric and/or social reason, which in the opinion
- •of the principal investigator, would prohibit the understanding of the informed
- •consent and/or make the administration of study drug hazardous or obscure the
- •interpretation of adverse events.
- •i) History of hepatitis B or C, or alcohol induced liver disease.
- •- Physical and Laboratory Test Findings
- •a) Evidence of organ dysfunction or any clinically significant deviation from normal
- •in physical examination, vital signs, ECG or clinical laboratory determinations.
- •b) Positive blood screen for hepatitis B surface antigen, or hepatitis C antibody.
- •- Allergies and Adverse Drug Reactions
- •a) History of allergy to BMS-663513 or related compounds.
- •- Prohibited Therapies and/or Medications
- •a) Exposure to any investigational products within 4 weeks prior to Day 1 of
- •b) Use of any immunosuppressing treatments including corticosteroids,
- •cyclosporine, mycophenolate mofetil (CellCept®), chemotherapy, radiation, etc,
- 另有 3 项未显示
研究者
相似试验
未知
1 期
Phase 1 Study of BMS-833923 (XL139)CancerJPRN-jRCT2080221644Bristol-Myers K.K.27
终止
1 期
A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid MalignanciesAdvanced Solid MalignanciesNCT00351325Bristol-Myers Squibb45
尚未招募
不适用
Phase 1b Multiple Ascending Dose Study of BMS-833923 (XL139) Administered in Combination with Cisplatin and Capecitabine as First-Line Therapy in Patients with Inoperable Metastatic Gastric, Gastroesophageal, or Esophageal AdenocarcinomasGastric/Gastroesophageal or Esophageal Adenocarcinomas - cancer of the stomach and/or esophagous10017991NL-OMON34104Bristol-Myers Squibb5
已完成
不适用
A Phase 1/2 Multicenter Study of BMS-986012 in Subjects with Relapsed / Refractory Small Cell Lung Cancer (CA001-030)small cell lung cancerneoplasms in the lungNL-OMON43272Bristol-Myers Squibb6
进行中（未招募）
1 期
BMS-986012 in Relapsed/Refractory SCLCMedDRA version: 18.1Level: LLTClassification code 10041071Term: Small cell lung cancer stage unspecifiedSystem Organ Class: 100000004864Small Cell Lung CancerEUCTR2014-002372-89-NLBristol-Myers Squibb International Corporation170